Sensorium Therapeutics Inc. has identified alkylated derivatives of mesembrine or mesembrenone acting as serotonin transporter (SERT) and/or phosphodiesterase PDE4 inhibitors reported to be useful for the treatment of anxiety, depression and stress disorders.
Rome Therapeutics Inc. has synthesized 4’-halomethyl-cytidine phosphoramidate compounds acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase inhibitors reported to be useful for the treatment of viral infections, cancer, inflammation, neurodegeneration and immunological disorders.
Shenzhen Borui Pharmaceutical Technology Co. Ltd. has disclosed Mas-related G-protein coupled receptor member X4 (MRGPRX4; SNSR5; SNSR6) antagonists reported to be useful for the treatment of autoimmune disease, cancer and more.
Researchers from The Cleveland Clinic Foundation continue to build intellectual property to protect their invention of a portable device for regulating the flow of cerebrospinal fluid (CSF) from a patient.
Evopoint Biosciences Co. Ltd. has synthesized probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) inhibitors reported to be useful for the treatment of cancer.
Parmedics Inc. has described proteinase-activated PAR2 receptor antagonists reported to be useful for the treatment of asthma, cancer, osteoarthritis, migraine, chronic pain, inflammatory and vascular disorders.
Beijing Primegene Therapeutics Co. Ltd. has divulged thioether compounds acting as transient receptor potential cation channel subfamily V member 3 (TRPV3) antagonists reported to be useful for the treatment of pain, pruritus, inflammation, fever, cystitis, irritable bowel syndrome, cough and alopecia.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has identified thiadiazolyl derivatives acting as DNA polymerase θ (POLθ, POLQ) inhibitors reported to be useful for the treatment of cancer.
Flagship Pioneering Innovations VI LLC has disclosed ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of fibrosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), Parkinson’s disease and cancer.
Scientists at Cerevance Inc. and Cerevance Ltd. have described potassium channel subfamily K member 13 (KCNK13; THIK-1) blockers reported to be useful for the treatment of fibrosis, depression, diabetes, gout, psoriasis, atherosclerosis, inflammatory bowel disease and traumatic brain injury.
RSS
